Cytodyn Inc (CYDY)

[Cynmark24]

Did I just see a trade at 40 cents?

Apologies if the following article has already been posted.

https://www.smarteranalyst.com/brief/h-c-wainwright-thinks-cytodyn-incs-stock-is-going-to-recover/

Wainwright seems to be the only analyst in the world who has supported CYDY over the years. Having just one seems almost insulting. Actually I don't know if I should be insulted or just plain depressed. Question in my mind today is whether or not just the weaker hands will bail or the stronger ones as well.


H.C. Wainwright Thinks CytoDyn Inc’s Stock is Going to Recover

Christine Brown-July 13, 2018, 7:14 AM EDTSHARE ON:     
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on CytoDyn Inc (NYSEArca: CYDY) today and set a price target of $1.50. The company’s shares closed yesterday at $0.44, close to its 52-week low of $0.41.

Selvaraju observed:

“Valuation and risks. Our 12-month price target is derived from a market value of the firm at $470M, which includes a discounted cash flow-based asset value for PRO 140 in the HIV indication alone, with 15% discount rate, 2% terminal growth rate, and 80% probability of success. Investment risks include: (1) failure of PRO 140 in clinical trials; (2) failure of PRO 140 to secure regulatory approval; (3) failure of PRO 140 to achieve commercial success due to market size, penetration rate, and/ or competition; and (4) dilution risk.”

According to TipRanks.com, Selvaraju is a 3-star analyst with an average return of 1.8%and a 47.1% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for CytoDyn Inc with a $1.50 average price target.

See today’s analyst top recommended stocks >>

Based on CytoDyn Inc’s latest earnings release for the quarter ending February 28, the company reported a quarterly GAAP net loss of $17.95 million. In comparison, last year the company had a GAAP net loss of $6.83 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CytoDyn, Inc. is a biotechnology company, which is focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of human immunodeficiency virus infection. CytoDyn was founded by Allen D. Allen on May 2, 2002 and is headquartered in Vancouver, WA.